D6A-25529-48407
4 vaccinations
7 coded responses
32 check-ins
6 free-text entries
2 call cases
- Sex
- Female
- Age at first dose
- 56-60
- ZIP prefix
- 210 / MD
- Registered
- 2021-02-20
- Relationship
- Self
- Race
- White
- Ethnicity
- Not Hispanic or Latino
Timeline
-
2021-02-20
Registered in v-safe
-
2021-02-20
Dose 1 — Moderna
- 2021-02-20
-
2021-02-21
Health check-in — days 1–6 daily, dose 1Feeling: Good · Site: Pain · Fatigue or tirednessAdult check-in
- 2021-02-22
- 2021-02-23
- 2021-02-25
- 2021-02-26
- 2021-02-27
- 2021-03-06
- 2021-03-13
-
2021-03-20
Dose 2 — Moderna
- 2021-03-20
-
2021-03-21
Survey response — days 1–6 daily, dose 2MedDRA: Injection site swelling, Lymphadenopathy — Feeling: Fair · Site: Pain · Chills, Joint pains, Fatigue or tirednessFree text: Swollen gland near gluteal injection siteMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-22
-
2021-03-23
Survey response — days 1–6 daily, dose 2MedDRA: Injection site erythema, Rash erythematous, Swelling — Feeling: Good · Site: Redness, SwellingFree text: Gluteal injection site was red, nearby gland on hip looked sunburned and was a bit puffy.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-24
-
2021-03-25
Survey response — days 1–6 daily, dose 2MedDRA: Lymph node pain — Feeling: Good · Site: RednessFree text: Lymph node near injection site still a bit sore. Not problematic.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-03-26
Survey response — days 1–6 daily, dose 2MedDRA: Injection site reaction, Lymph node pain — Feeling: GoodFree text: Gland near injection is tenderMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
- 2021-03-28
- 2021-04-03
- 2021-04-11
-
2021-04-17
Survey response — day 28, dose 2MedDRA: Acute febrile neutrophilic dermatosis, Increased tendency to bruise, Muscular weakness, Office visit, Pre-existing disease, Rash — Feeling: Fair · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultation, Outpatient clinic or urgent care clinic visitFree text: Severe rash, saw dermatologist and they suspect Sweet syndrome. Accompanied by mild muscle weakness and spontaneous bruising near joints. Awaiting biopsy of skin rash for diagnosis. I am a stage lung cancer patient on Tagrisso.MedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-04-17
Report sent to call center — day 28, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
-
2021-04-24
Survey response — day 35, dose 2MedDRA: Acute febrile neutrophilic dermatosis, Arthralgia, Contusion, Neutrophil percentage increased, Peripheral swelling, Rash, Unevaluable event — Feeling: Poor · Be unable to work, Be unable to do your normal daily activities, Get care from a doctor or other healthcare professional · Telehealth, virtual health, or email health consultationFree text: Symptoms: Rash, swelling and bruising in legs, joint pain. Suspected Sweet syndrome, diagnosis pending biopsy. C-reactive protein 1.94mg/dL (standard range <0.29mg/dL), neutrophil% 76.9% (std range 40-70). Rash began 4/13. Began prednisone today, exc respons · Healthcare visit (other): PrescriptionMedDRA releases: 2021-09,2023-04,2024-11 · check-in free text available
-
2021-04-24
Report sent to call center — day 35, dose 2Be unable to work · Be unable to do your normal daily activities · Get care from a doctor or other healthcare professional1 call case(s)
- 2021-05-01
- 2021-06-19
- 2021-09-18
-
2021-12-09
Dose 3 — Pfizer-BioNTech
- 2022-03-20
- 2022-04-01
-
2022-09-07
Dose 4 — Pfizer-BioNTech
- 2022-09-21
- 2022-09-28
- 2022-10-05
- 2022-10-12
- 2022-10-19
- 2022-12-07
- 2023-03-08
Vaccinations
| Dose | Date | Manufacturer | Co-administered |
|---|---|---|---|
| 1 | 2021-02-20 | Moderna | |
| 2 | 2021-03-20 | Moderna | |
| 3 | 2021-12-09 | Pfizer-BioNTech | No |
| 4 | 2022-09-07 | Pfizer-BioNTech | No |
Call center
2 call center cases
2 unsuccessful
1 wait over 3 months for a first call
Free text
Release 6 — days 1–6 daily, dose 2
Systemic reaction (other): Swollen gland near gluteal injection site
Systemic reaction (other): Gluteal injection site was red, nearby gland on hip looked sunburned and was a bit puffy.
Systemic reaction (other): Lymph node near injection site still a bit sore. Not problematic.
Systemic reaction (other): Gland near injection is tender
Release 7 — day 28, dose 2
Symptoms: Severe rash, saw dermatologist and they suspect Sweet syndrome. Accompanied by mild muscle weakness and spontaneous bruising near joints. Awaiting biopsy of skin rash for diagnosis. I am a stage lung cancer patient on Tagrisso.
Release 7 — day 35, dose 2
Symptoms: Rash, swelling and bruising in legs, joint pain. Suspected Sweet syndrome, diagnosis pending biopsy. C-reactive protein 1.94mg/dL (standard range <0.29mg/dL), neutrophil% 76.9% (std range 40-70). Rash began 4/13. Began prednisone today, exc respons cut off by CDC
Healthcare visit (other): Prescription
Each entry is dated by the survey it was written in (the CDC re-sent the releases with survey dates in 2025); click a date to see that survey response. The CDC cut some text off at about 250 characters: symptoms in every release, and the other two fields in releases 9-12. Those entries are marked "cut off by CDC".
MedDRA terms by release
| Field | Preferred term | 2021-09 | 2023-04 | 2024-11 |
|---|---|---|---|---|
| HCVO | Unevaluable event | ✓ | ✓ | ✓ |
| SD | Acute febrile neutrophilic dermatosis | ✓ | ✓ | ✓ |
| SD | Arthralgia | ✓ | ✓ | ✓ |
| SD | Contusion | ✓ | ✓ | ✓ |
| SD | Hypoaesthesia | · | · | ✓ |
| SD | Increased tendency to bruise | ✓ | ✓ | ✓ |
| SD | Muscular weakness | ✓ | ✓ | ✓ |
| SD | Neutrophil percentage increased | ✓ | ✓ | ✓ |
| SD | Office visit | ✓ | ✓ | ✓ |
| SD | Peripheral swelling | ✓ | ✓ | ✓ |
| SD | Pre-existing disease | ✓ | ✓ | ✓ |
| SD | Rash | ✓ | ✓ | ✓ |
| SRO | Injection site erythema | ✓ | ✓ | ✓ |
| SRO | Injection site reaction | ✓ | ✓ | ✓ |
| SRO | Injection site swelling | ✓ | ✓ | ✓ |
| SRO | Lymph node pain | ✓ | ✓ | ✓ |
| SRO | Lymphadenopathy | ✓ | ✓ | ✓ |
| SRO | Rash erythematous | ✓ | ✓ | ✓ |
| SRO | Swelling | ✓ | ✓ | ✓ |
✓ active code · ○ coded but marked inactive · blank = not in that release